Format

Send to

Choose Destination
J Immunother Cancer. 2017 Apr 18;5:31. doi: 10.1186/s40425-017-0232-7. eCollection 2017.

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients.

Author information

1
Institut Gustave Roussy, University of Paris-Sud, Department of Cancer Medicine, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
2
Institut Paoli-Calmettes, Department of Medical Oncology, 13009 Marseille, France.

Abstract

BACKGROUND:

Prostate cancer is one of the most common cancers in men and the fourth leading cause of cancer mortality worldwide. Although major progress has been achieved in the last years for patients with metastatic castrate-resistant prostate cancer (mCRPC), thanks to next-generation androgen receptor axis targeted drugs, taxanes, and bone-targeted agents, immunotherapy has not been widely approved and used for the treatment of prostate cancer. Two large studies with ipilimumab, an anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4) antibody reported improved progression-free survival, but not statistically improved overall survival at the primary analysis (CA184 043 and CA184 095).

CASE PRESENTATION:

Here, we report on two patients who received ipilimumab in these trials and are still in long-term complete remission with a follow-up of 64 and 52 months respectively after the initiation of ipilimumab. Immunohistochemical staining for hMLH1, hMSH2, hMSH6 and PMS2 was performed on archival prostate biopsy samples from one of the two patients; they exhibited normal protein expression. Interestingly for this patient, a high CD3+ and CD8+ T cell infiltration was observed on archival prostate biopsies as well as Treg FoxP3+ T cells.

CONCLUSION:

Ipilimumab produces clinical activity in patients with CRPC, including very long responders with no detectable residual disease.

KEYWORDS:

Immunotherapy; Ipilimumab; Metastatic castrate-resistant prostate cancer

PMID:
28428880
PMCID:
PMC5394619
DOI:
10.1186/s40425-017-0232-7
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center